Take part in a paid clinical trial

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies. This trial is being held in Melbourne.

Phenylketonuria (PKU) is a rare condition that people are born with. It happens when the body cannot properly break down a part of protein called phenylalanine.

When phenylalanine builds up in the blood, it can damage the brain and cause learning problems, nerve problems, and mental health issues if it is not treated.

People with PKU are treated by eating very low‑protein diets or using special medicines, but these treatments can be hard to follow and do not work perfectly. The study drug is being developed to potentially treat PKU.

The study drug is being developed for rare genetic liver diseases. These diseases happen because of a mistake in the DNA called a “nonsense mutation.” This mistake acts like a stop sign in the middle of an important gene, so the body can’t make the full protein it needs. Without these proteins, the body’s metabolism doesn’t work properly, leading to serious conditions like phenylketonuria (PKU), organic acidemias, and urea cycle disorders. 

The study drug works by sending a special molecule into the liver using tiny fat-based particles. This molecule helps the body “read through” the stop signs in the gene, so it can finish making the protein correctly. In other words, it fixes the root cause of the problem instead of just treating symptoms. 

Right now, there are no approved treatments that repair these mutations. Current options like strict diets or liver transplants only manage symptoms and can be very hard on patients. The study drug would be the first treatment designed to actually correct the genetic error, giving the body the ability to make the missing protein and potentially change the course of these diseases. Making this study an important trial to move medicine forward.